FDA 483 - Boston Medical Products, Inc. - July 12, 2023

An FDA inspection of Boston Medical Products, Inc., a distributor in Shrewsbury, MA, revealed a significant procedural deficiency. The firm failed to develop written procedures for the surveillance, receipt, evaluation, and reporting of post-marketing adverse drug experiences for its approved drug product, Steritalc. This indicates a lack of essential controls for drug safety reporting.